Education
About Us
Working with TipRanks
Follow Us
BridgeBio Oncology Therapeutics (BBOT)
NASDAQ:BBOT
BBOT Stock Chart & Stats
$12.59
--
Market closed
$12.59
--
Day’s Range― - ―
52-Week Range$8.50 - $14.87
Previous CloseN/A
VolumeN/A
Average Volume (3M)344.97K
Market Cap
$913.07M
Enterprise ValueN/A
Total Cash (Recent Filing)$468.29M
Total Debt (Recent Filing)$2.89M
Price to Earnings (P/E)―
Beta0.14
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding79,988,686
10 Day Avg. Volume232,276
30 Day Avg. Volume344,973
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.93
Price to Sales (P/S)0.00
P/FCF Ratio-228.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$22.83Price Target Upside81.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Efficacy And Competitive PositioningMonotherapy and combination data for BBO-8520 report strong response rates and meaningful duration of benefit, with single-agent efficacy appearing comparable to leading rivals in KRAS-targeted oncology.
Pipeline Breadth And CatalystsA diversified oncology pipeline targeting high-prevalence tumor types and differentiated mechanisms presents multiple clinical readouts in 2026 that could drive material value inflection.
Safety And TolerabilityBBO-8520 shows a favorable safety profile in early clinical data with no major liver enzyme elevations or heart rhythm issues, supporting use in combination regimens without adding significant toxicity concerns.
Bears Say
Clinical Development RiskClinical setbacks or inability to advance key assets into pivotal trials would undermine expected milestones and significantly reduce potential upside.
Financial PerformanceA wider-than-expected net loss per share raises concern about the company's expense run rate and could pressure investor sentiment and valuation.
Regulatory And Commercialization RiskFailure to secure regulatory approvals or to execute successful commercialization plans could limit revenue realization even if clinical outcomes are favorable.
BridgeBio Oncology Therapeutics News
BBOT FAQ
What was BridgeBio Oncology Therapeutics’s price range in the past 12 months?
BridgeBio Oncology Therapeutics lowest stock price was $8.50 and its highest was $14.87 in the past 12 months.
What is BridgeBio Oncology Therapeutics’s market cap?
BridgeBio Oncology Therapeutics’s market cap is $913.07M.
When is BridgeBio Oncology Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were BridgeBio Oncology Therapeutics’s earnings last quarter?
Currently, no data Available
Is BridgeBio Oncology Therapeutics overvalued?
According to Wall Street analysts BridgeBio Oncology Therapeutics’s price is currently Undervalued.
Does BridgeBio Oncology Therapeutics pay dividends?
BridgeBio Oncology Therapeutics does not currently pay dividends.
What is BridgeBio Oncology Therapeutics’s EPS estimate?
BridgeBio Oncology Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BridgeBio Oncology Therapeutics have?
BridgeBio Oncology Therapeutics has 79,988,686 shares outstanding.
What happened to BridgeBio Oncology Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BridgeBio Oncology Therapeutics?
Currently, no hedge funds are holding shares in BBOT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BridgeBio Oncology Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.83 (81.36% Upside)
$22.83 (81.36% Upside)
Hedge Fund Trend
Increased
By 7.7M Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.62%
12-Months-Change
Fundamentals
Return on Equity
2.53%
Trailing 12-Months
Asset Growth
3.96%
Trailing 12-Months
Company Description
BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.
BBOT Stock 12 Month Forecast
Average Price Target
$22.83
▲(81.36% Upside)
Technical Analysis
dMY Squared Technology Group, Inc. Class A
―
―
―
Four Leaf Acquisition Corporation Class A
―
Quetta Acquisition Corp.
―